High-dose infliximab for treatment of pediatric ulcerative colitis: A survey of clinical practice

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 11

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

506

HTML

2682

Figures (1-1)

246

Tables (1-5)

238

Sum=3672

Mar 21, 2012 (publication date) through Nov 4, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Mar 21, 2012; 18(11): 1229-1234
Published online Mar 21, 2012. doi: 10.3748/wjg.v18.i11.1229

Table 5 Side effects and adverse reactions

Answer options	Percentage (n)
None	64.1 (50)
Antibodies to infliximab	17.9 (14)
Infusion reaction or delayed hypersensitivity reaction	16.7 (13)
Worsening ulcerative colitis	14.1 (11)
Infection	12.8 (10)
Headache	9.0 (7)
Arthralgia	9.0 (7)
Development of autoimmune antibodies (e.g., antinuclear antibodies, anti-dsDNA antibodies)	5.1 (4)
Other	2.6 (2)
Profound anemia	1.3 (1)
Oncologic process	0 (0)
Neurologic event (e.g., neuritis, neuropathy)	0 (0)

78 respondents.

Citation: Nattiv R, Wojcicki JM, Garnett EA, Gupta N, Heyman MB. High-dose infliximab for treatment of pediatric ulcerative colitis: A survey of clinical practice. World J Gastroenterol 2012; 18(11): 1229-1234
URL: https://www.wjgnet.com/1007-9327/full/v18/i11/1229.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i11.1229